Furthermore, the therapeutic effects of CD25-targeted NIR-PIT extended to distant non-treated tumors in a tumor-specific manner, because activated CD8+ T and NK cells were increased in the non-treated tumor after this therapy. Here, CD8A is linked to neoplasm.